Checkpoint inhibitor shrinks advanced squamous cell skin cancer

June 4, 2018, University of Texas M. D. Anderson Cancer Center

Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine.

"These results mark a potential paradigm shift in the treatment of patients with advanced cutaneous , who to date have had very limited results with chemotherapy and targeted therapies," said lead author Michael Migden, M.D., associate professor of Dermatology and of Head and Neck Surgery.

Migden is principal investigator of the international, multicenter phase II registrational clinical trial of cemiplimab, an that works by blocking PD1, a surface receptor on T cells that shuts down immune response to .

Cutaneous squamous cell carcinoma is the second most common skin cancer, with an estimated 1 million new cases diagnosed annually. More than 95 percent of patients are cured by surgery and radiation at the disease's early stages. But for the fraction who progress, there are no systemic therapies approved as a standard of care, the researchers note.

At a median follow-up of 7.9 months, 28 of 59 patients with metastatic disease (47.5 percent) had an objective response to cemiplimab, defined as at least 30 percent tumor shrinkage observed via imaging. Four were complete responses, 24 had partial responses, and 82 percent of responders remain on the drug.

"Patients continue to do well, so median progression-free survival and overall survival have not been reached yet," said Migden, a Mohs surgeon and dermatologic oncologist at MD Anderson. The durable disease control rate of responders plus those with stable disease for at least 105 days was 61 percent. Migden notes that response rates to chemotherapy regimens or targeted therapy against the epidermal growth factor receptor (EGFR) now used against advanced cutaneous squamous cell carcinoma range from 15-25 percent, with many debilitating side effects.

Immunotherapies pose risks of inflammatory side effects that have to be monitored, but otherwise have fewer day-to-day complications than chemotherapy and EGFR inhibitors, Migden said.

Common side effects in the cemiplimab phase II trial were diarrhea, fatigue, nausea, constipation, and rash. Four patients (6.8 percent) had to discontinue treatment. Three patients died of adverse events during the trial, but the deaths were not considered related to treatment.

Median age of patients in the phase II trial was 71, with 33 (55.9 percent) having received prior systemic therapy and 50 (84.7 percent) having received radiotherapy.

In the phase I trial of patients with metastatic or locally advanced but inoperable disease, 13 of 26 (50 percent) had a partial response. At 11 months median follow-up, seven patients remained in response. Two (7.7 percent) had to discontinue treatment due to adverse events. Median age was 73.

The U.S. Food and Drug Administration has granted an application for breakthrough therapy status for the drug, providing a faster potential route for FDA approval. Regeneron Pharmaceuticals, Inc., and Sanofi are co-developing cemiplimab.

Cutaneous squamous cell carcinoma develops from genetic damage caused by exposure to UV light. These tumors have a high mutation burden, providing a target-rich environment for immune system attack and this cancer also is strongly associated with immune suppression. Those factors made it a strong candidate for PD1 inhibition, which unleashes the immune system to attack cancer.

The clinical trials are funded by Regeneron and Sanofi.

Cutaneous squamous cell carcinoma is not included in national cancer registries, so the incidence of the disease and its mortality rates are unknown. Estimates or annual diagnoses range from 700,000 to 1 million. One study estimated that between 3,900 and 8,700 people died from this cancer in 2012.

Explore further: Erdafitinib shows promise in urothelial cancer patients with specific mutations

Related Stories

Erdafitinib shows promise in urothelial cancer patients with specific mutations

June 3, 2018
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated and achieved a robust response for patients ...

Phase II trial shows activity of durvalumab in recurrent/metastatic head and neck cancer

February 13, 2018
Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow ...

Avelumab safe and yields durable responses for patients with advanced Merkel cell carcinoma

April 3, 2017
The immunotherapeutic avelumab (Bavencio) was well tolerated by patients with advanced Merkel cell carcinoma, and the majority of those whose cancer responded to avelumab treatment had durable responses, according to results ...

Dual inhibition of IDO1 and PD-L1 safe in patients with advanced solid tumors

April 17, 2018
An immunotherapy treatment combining the IDO1 inhibitor epacadostat and the PD-L1 inhibitor durvalumab was found to be safe in patients with advanced solid tumors, with safety data similar to treatment with durvalumab alone, ...

Cabozantinib shows significant first-line activity for differentiated thyroid cancer

February 13, 2018
Results of a new phase II clinical trial indicate that cabozantinib offers an active therapy option for patients with differentiated thyroid cancer (DTC) that has progressed following surgery and treatment with radioactive ...

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

Recommended for you

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.